<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02159976</url>
  </required_header>
  <id_info>
    <org_study_id>B-1403/243-003</org_study_id>
    <nct_id>NCT02159976</nct_id>
  </id_info>
  <brief_title>Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea</brief_title>
  <official_title>A Prospective, Multi-center, Randomized, Open-label, Parallel Design Clinical Trial to Compare 10-day Sequential Therapy and 14-day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SK Chemicals Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To compare 10-day sequential therapy and 14-day modified bismuth quadruple therapy and
           to establish more effective first-line regimen for the eradication of Helicobacter
           pylori in Korea.

        2. To evaluate the effect of H. pylori eradication therapy on the symptom improvement of
           functional dyspepsia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Emerging evidence shows that the eradication rate of proton pump inhibitor (PPI)-based triple
      therapy for the first-line treatment of Helicobacter pylori has decreased. The reason for the
      decrease in the efficacy of PPI-based triple therapy is mainly due to the increase in the
      resistance against clarithromycin. Sequential therapy seems to be more effective than the
      PPI-based triple therapy, however, the eradication rate of sequential therapy in Korea, which
      is mostly under 80%, is still not satisfactory. Modified bismuth quadruple therapy which
      replace metronidazole with amoxicillin (contained PPI, bismuth, tetracycline and amoxicillin)
      can be a promising regimen because the antibiotic resistance rate of tetracycline and
      amoxicillin are relatively low in Korea and amoxicillin is more easy to take in comparing
      with metronidazole. Therefore, the aim of this study is to compare 10-day sequential therapy
      and 14-day modified bismuth quadruple therapy and to establish more effective first-line
      regimen for the eradication of Helicobacter pylori in Korea.

      In addition, previous studies reported that H. pylori infection also associated with
      functional dyspepsia (FD) and recommended H. pylori eradication in patients with FD. However,
      until now, there was no randomized prospective study in Korea, therefore the another aim of
      this study is to evaluate the effect of H. pylori eradication therapy on the symptom
      improvement of FD.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the percentage of participants with successful H. pylori eradication in each groups.</measure>
    <time_frame>4-6 weeks after termination of eradication therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the percentage of patients whose drug compliance is more than 85%</measure>
    <time_frame>4-6 weeks after termination of eradication therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the percentage of adverse event in each treatment groups</measure>
    <time_frame>4-6 weeks after termination of eradication therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in functional dyspepsia symptom on the 5-Likert scale</measure>
    <time_frame>6, 26, and 50 weeks after termination of eradication therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Sequential therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pantoprazole 40mg bid 10 days (D1-D10), amoxicillin 1000mg bid 5 days (D1-D5), clarithromycin 500mg bid 5 days (D6-D10), metronidazole 500mg tid 5 days (D6-D10)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modified bismuth quadruple therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pantoprazole 40mg bid 14 days (D1-D14) , amoxicillin 1000mg bid 14 days (D1-D14), tetracycline 1000mg bid 14 days (D1-D14), bismuth 600mg bid 14 days (D1-D14)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole</intervention_name>
    <arm_group_label>Sequential therapy</arm_group_label>
    <arm_group_label>Modified bismuth quadruple therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <arm_group_label>Sequential therapy</arm_group_label>
    <arm_group_label>Modified bismuth quadruple therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <arm_group_label>Sequential therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <arm_group_label>Sequential therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracycline</intervention_name>
    <arm_group_label>Modified bismuth quadruple therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth</intervention_name>
    <arm_group_label>Modified bismuth quadruple therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female Korean Adult (Aged â‰¥ 18 years)

          -  Patients who diagnosis of H. pylori infection by any of following three methods

               -  positive rapid urease test (CLOtest)

               -  histologic evidence of H. pylori by modified Giemsa staining

               -  positive 13C-urea breath test

        Exclusion Criteria:

          -  Age under 18 years

          -  Previous eradication treatment for H. pylori

          -  Patients who took any drug which could influence the study results such as proton pump
             inhibitor, H2 blocker, mucosal protective agent and antibiotics

          -  History of gastrectomy

          -  Advanced gastric cancer or other malignancy

          -  Abnormal liver function or liver cirrhosis

          -  Abnormal renal function or chronic kidney disease

          -  Other severe concurrent diseases

          -  Previous allergic reactions to the study drugs

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nayoung Kim, M.D., Ph.D.</last_name>
    <phone>82-31-787-7008</phone>
    <email>nayoungkim49@empas.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nayoung Kim, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2014</study_first_submitted>
  <study_first_submitted_qc>June 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2014</study_first_posted>
  <last_update_submitted>May 19, 2015</last_update_submitted>
  <last_update_submitted_qc>May 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Nayoung Kim</investigator_full_name>
    <investigator_title>Professor, M.D, Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 5, 2016</submitted>
    <returned>June 10, 2016</returned>
    <submitted>November 1, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

